English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

High-dose chemotherapy by following autologous stem cell transplant (ASCT) is a standard treatment of multiple myeloma (MM), relapse of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphomas (NHL). Monitoring of clinical and biochemical characteristics, as well as post-transplant parameters, all point to the importance of mobilization potential. Aim: To evaluate the association of early recovery of neutrophil granulocytes ≥0.5 x 109 /L after 11 days of transplantation (ANC500_11), platelets ≥20 x 109 /L after 13 days of transplantation (PLT20_13) with gender, age, duration of mobilization, as well as radiotherapy or chemotherapy, dose CD34+ cells in the apheresis product and therapeutic response. Material and Methods: The retrospective study included 100 patients, out of which 51 patients with MM, 27 with NHL and 22 with HL, in the period from November 2015, ending December 2018. Results: The median age of the patient was 53(20-67) years. According to the DSS, 69% were in IIIA, while 12.5% of patients were in the IIIB clinical stage. According to the Ann-Arbor staging 92% patients were in the II or III clinical stage. The mediana number of CD34+ cells in the apheresis product was 6.7×106 /kgBM. The median in all three mobilization attempts was 6 days. Engraftment is most often detected during the 11th day. In 78% of patients, mobilization was successful in the first attempt (≥2.0x106 /kgBM) among which 86% were MM and 69,4% of lymphomas (p 0.05) in relation to the recovery of ANC500_11 and PLT20_13. Conclusion: Satisfactory CD34+ cellular yield can be provided in the first mobilization attempt in most of the patients using of GCS-F, while in the further mobilization attempts plerixafor was necessery. As opposed to gender, age, duration of mobilization and therapeutic response have no impact on ANC500_11 and PLT20_13.

Mobilization potential of patients with lymphomas and multiple myeloma involved in autologous stem cell transplant